3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Venous Thromboembolism
8
Venous Thrombosis
4
Neoplasms
4
Pulmonary Embolism
2
Lung Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Thrombocytopenia
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Darbepoetin alfa
3
Tinzaparin
2
Epoetin Alfa
2
Cisplatin
2
sotorasib
1
romiplostim
1
pegfilgrastim
1
continuous erythropoietin receptor activator
1
Tretinoin
1
Rivaroxaban
1
Nadroparin
1
Gemcitabine
1
Fondaparinux
1
Docetaxel
1
Dalteparin
1
Carboplatin
1
2,2'-dithiodiethanesulfonic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Tinzaparin
×
Classical hematology
×
Clear all
NCT03090880
2022-11-17
PROVE
Assistance Publique - Hôpitaux de Paris
Phase 3
Terminated
59 enrolled
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled